HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final Rule To Enforce FTC's ‘Made In USA’ Policy Reveals Commission's Split On Limits To Authority

Executive Summary

FTC finalizes “Made in USA” rule codifying longstanding policy that wasn’t enforced. The rule imposes fines up to $43,280 per violation, but Commissioner Christine Wilson says rule is another example of commission exceeding its authority.

You may also be interested in...



In Parting FTC Shot, Wilson Pins Negative Option Proposal To Democrat Majority Overreach

“The rule would capture misrepresentations regarding the underlying product or service wholly unrelated to the negative option feature,” says Christine Wilson in dissenting statement on FTC’s notice of proposed rulemaking.

FTC ‘Dark Patterns' Enforcement Policy Darkens Public Input On Rule, Commissioner Wilson Argues

Wilson’s dissenting statement isn’t first time she's disagreed with Democrat majority on the five-seat commission after four years of a Republican majority. Her statement made clear her argument the commission has over-stepped its authorities more than once.

Restoring FTC Monetary Relief Authority: For Commission Members, Not One Size Fits All

House already passed legislation to amend Sec. 13(b) of FTC regulations and make explicit its authority to obtain injunctive and equitable relief in court, but differences in Democrat and Republican commission appointees' views on the authority was a key topic of discussion during a recent Energy and Commerce hearing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel